With the discovery of oncogenic driver mutations in epidermal growth factor receptor (EGFR) and rearrangements in anaplastic lymphoma kinase (ALK) and ROS1, there has been a paradigm shift from a “one size fits all” approach to lung cancer treatment to more precise and rational targeted therapy (3, 4). This evidence concerns the gene ALK and lung carcinoma.